<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75434">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01757444</url>
  </required_header>
  <id_info>
    <org_study_id>2012 - A00731 - 42</org_study_id>
    <secondary_id>EVAL CLIN - VENTILATEUR</secondary_id>
    <nct_id>NCT01757444</nct_id>
  </id_info>
  <brief_title>Non Invasive Ventilation : Efficacy of a New Ventilatory Mode in Patients With OHS</brief_title>
  <official_title>Clinical Benefits and Tolerance to a New Ventilatory Mode in Patients With Obesity Hypoventilation Syndrome (OHS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Nationale pour le Traitement à Domicile de l'Insuffisance Respiratoire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Nationale pour le Traitement à Domicile de l'Insuffisance Respiratoire</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In 2012, it has announced the availability of the new ventilator (BiPAP- A40), which could
      offer potential advantages over fixed level pressure support, in particular, in patients
      with obesity hypoventilation syndrome (OHS). One of the key benefits of the BiPAP A40 is an
      innovative ventilation mode called AVAPS-AE, which automatically maintains airway patency
      while delivering the correct level of ventilation each user requires, whatever their body
      position or sleep stage. AVAPS-AE mode is also aimed to help the clinicians during the
      initial titration of therapy, while providing long term comfort and assuring therapy
      compliance. However, studies on the physiologic and clinical effects have not yet been
      performed. The aim of our singled-blind randomised multicentre controlled trial is to
      prospectively investigate the effects of  BiPAP with the spontaneous/timed (S/T) or the
      AVAPS-AE ventilation mode over 8 weeks on sleep quality, ventilation pattern, gas exchange,
      symptoms, body composition, level of physical activity and health-related quality of life in
      OHS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy on sleep quality, symptoms, physical activity and quality of life
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>CHANGE IN SLEEP QUALITY</measure>
    <time_frame>Day 1 and Day 61</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Sleep stage, micro arousals, apnea/hypopnea index...</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CHANGE IN GAZ EXCHANGE</measure>
    <time_frame>Day 1 and Day 61</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>CHANGE IN QUALITY OF LIFE/ LEVEL OF PHYSICAL ACTIVITY/ BODY COMPOSITION</measure>
    <time_frame>Day 1 and Day 61</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity Hypoventilation Syndrome</condition>
  <arm_group>
    <arm_group_label>BiPAP - A40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BiPAP with AVAPS AE mode</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BiPAP- ST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving BiPAP- ST at home</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BiPAP - A40</intervention_name>
    <description>Patients receiving BiPAP AVAPS - AE ventilatory mode at home</description>
    <arm_group_label>BiPAP - A40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BiPAP - ST</intervention_name>
    <description>Patients receiving BiPAP- ST mode at home.</description>
    <arm_group_label>BiPAP- ST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman, stable patient with obesity hypoventilation syndrome, naives of non
             invasive ventilation.

          -  PaCO2 ≥ 45 mmHg.

          -  PaO2 &lt; 70 mmHg

          -  BMI ≥ 30Kg. m2

        Exclusion Criteria:

          -  Chronic obstructive pulmonary disease

          -  Neuromuscular disease

          -  Scoliosis

          -  Cardiac insufficiency

          -  Significant psychiatric disease

          -  Sleep apnea syndrome with central apnea index &gt; 10%

          -  Treatment with benzodiazepines at the inclusion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François MUIR, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association Nationale pour le Traitement à Domicile de l'Insuffisance Respiratoire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annabelle COUILLARD, Ph.D</last_name>
    <email>annabelle.couillard@yahoo.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier de Béziers</name>
      <address>
        <city>Beziers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut- Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cannes</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital du Bocage</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital La Milétrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de Bois Guillaume</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean François MUIR, Pr</last_name>
      <email>Jean-Francois.Muir@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>December 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Association Nationale pour le Traitement à Domicile de l'Insuffisance Respiratoire</investigator_affiliation>
    <investigator_full_name>COUILLARD Annabelle</investigator_full_name>
    <investigator_title>Coordinator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity Hypoventilation Syndrome</mesh_term>
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
